Navigation Links
OncoGenex Pharmaceuticals Announces Release of Two ASCO Abstracts: Impact of OGX-011 on Survival in Randomized Phase 2 Trial and Phase 1 Safety Data for OGX-427
Date:5/14/2009

ival benefit of OGX-011, anticipated clinical development activities, timing of these activities, the ability of future trials to demonstrate clinical benefit and the potential for regulatory approvals. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. These statements are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those described in the forward-looking statements.

The potential risks and uncertainties associated with forward-looking statements include, among others, the possibility that any benefit in patient survival will not be maintained or will become less substantial as patient survival follow up continues, risks that clinical trials will not be successful or confirm earlier clinical trial results, including the risk that the survival benefit will not be confirmed by a Phase 3 clinical trial, risks associated with obtaining funding from third parties or completing a financing necessary to support the costs and expenses of a Phase 3 clinical trial, the timing and costs of clinical trials and regulatory approvals will be different than management currently anticipates, risks relating to the development, safety and efficacy of therapeutic drugs and potential applications for these products and the risk factors set forth in the Company's filings with the Securities and Exchange Commission, including the Company's Annual Report on Form 10-K for fiscal year 2008. The Company undertakes no obligation to update the forward-looking statements contained herein or to reflect events or circumstances occurring after the date hereof.


'/>"/>
SOURCE OncoGenex Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3 4 5

Related biology technology :

1. OncoGenex Pharmaceuticals Clinical Programs to be Featured in Oral Presentations at the American Society of Clinical Oncology Annual Meeting
2. OncoGenex Reports First Quarter Financial Results
3. OncoGenex Pharmaceuticals to Release First Quarter Financial Results
4. OncoGenex Receives Confirmation from FDA on the Design of a Second Phase 3 Trial Evaluating OGX-011 for the Treatment of Advanced Prostate Cancer
5. OncoGenex Pharmaceuticals Named Life Sciences Company of the Year by LifeSciences British Columbia
6. OncoGenex Reports Financial Results for Fourth Quarter and Fiscal Year 2008 and Provides Outlook for 2009
7. OncoGenex Pharmaceuticals to Webcast Financial Results for Fourth Quarter and Fiscal Year 2008 and Provide Outlook for 2009
8. OncoGenex Provides Update on Two-Year Survival Data from Ongoing Phase 1/2 Clinical Trial of OGX-011 in Non-Small Cell Lung Cancer
9. OncoGenex To Present At The RBC Capital Markets 2008 Healthcare Conference
10. OncoGenex Reports Third Quarter Financial Results
11. OncoGenex Pharmaceuticals to Release Third Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/17/2013)... GA (PRWEB) May 17, 2013 Dr. ... Gynecology, and Women’s Health at the Albert Einstein College ... Oncology at the Montefiore Medical Center. He is ... Cancer Center and leads the Einstein Breast Cancer Working ... on translational breast cancer research. He also serves as ...
(Date:5/17/2013)... world-leading provider of scientific, technical and medical information products ... study in Reproductive BioMedicine Online ... an abnormal chromosomal composition can be identified by the ... classifying the risk of genetic abnormality without a biopsy. ... a retrospective study, using their predictive model to assess ...
(Date:5/17/2013)... , May 17, 2013  Cellular Biomedicine ... achieved 50% enrollment of the total projected enrollment ... the safety and preliminary efficacy of the medical ... for Knee Osteoarthritis (KOA). To date the trial ... The Phase I open label clinical ...
(Date:5/17/2013)... May 17, 2013 Men’s skin is biologically ... La-roche Posay ) and has been known to react more ... men may be far from puberty, other acne causing factors ... causing breakouts, and threatening skin with unsightly acne scars. Adult ... Men’s Health on how to reduce and prevent ...
Breaking Biology Technology:Joseph A. Sparano, MD, Named Vice Chair of ECOG-ACRIN Cancer Research Group 2Joseph A. Sparano, MD, Named Vice Chair of ECOG-ACRIN Cancer Research Group 3Breakthrough for IVF? 2Breakthrough for IVF? 3Cellular Biomedicine Group Achieves 50% Enrollment Milestone in Phase I Clinical Trial for Knee Osteoarthritis 2Adult Acne Treatment, Probiotic Action Shares New Insight on Why Men’s Skin Scars from Acne and How to Prevent It 2
... Carolina State University shows that size plays a key ... The researchers focused on nickel nanoparticles, which have interesting ... fields as diverse as energy production and nanoelectronics. ... nanofabrication the creation of materials that have very ...
... material graphene maintains its high thermal conductivity when supported ... material from a laboratory phenomenon to a useful component ... the April 9 issue of the journal Science. ... from the University of Texas at Austin, Boston College, ...
... ... Workshop on Electronic Regulatory Submissions , ... Rockville, MD (Vocus) April 8, 2010 -- Bringing its popular interactive ... host Preparing Compliant eCTD Submissions in Brussels, 5–7 May. This introductory workshop guides participants ...
Cached Biology Technology:Study shows that size affects structure of hollow nanoparticles 2With support, graphene still a superior thermal conductor 2RAPS to Host eCTD Submissions Workshop in Brussels 2RAPS to Host eCTD Submissions Workshop in Brussels 3
(Date:5/17/2013)... human-caused climate change may have little impact on ... of recent studies that predict their widespread extinction ... which appear in the journal Global Change ... a creature thought to be doomed: http://onlinelibrary.wiley.com/doi/10.1111/gcb.12253/abstract ... especially forest lizards, will be hard hit by ...
(Date:5/16/2013)... Bethesda, MD FASEB MARC (Maximizing Access to ... recipients for The Endocrine Society (ENDO) 95th Annual ... 2013. These awards are meant to promote the ... groups into the mainstream of the basic science ... scientists at the ENDO 2013 Annual Meeting. , ...
(Date:5/16/2013)... in neurodegenerative disease also plays a critical role in ... In a study of the common fruit fly, the ... responsible for sleeping and waking on a 24-hour rhythm. ... sleep-wake cycle is disturbed, making waking up on a ... discovery is particularly interesting because mutations in the human ...
Breaking Biology News(10 mins):Climate change may have little impact on tropical lizards 2Gene involved in neurodegeneration keeps clock running 2
... University at Buffalo’s Research Institute on Addictions (RIA) is ... the regulation of stress, stress-related behavior and anxiety. , ... of Mental Health is supporting this investigation. , ... reasons that people use and abuse marijuana is to ...
... vaccine that prevents HIV infection remains an important goal ... HIV vaccine candidates may not work in this way, ... Infectious Diseases (NIAID), part of the National Institutes of ... if administered prior to HIV infection, may reduce HIV ...
... of capturing a clear picture of a moving target. ... sometimes the motion is exactly what scientists want to ... mis-folding and assembly that seem to underlie a host ... , Now, chemists at the University of ...
Cached Biology News:The quest for an effective HIV vaccine presents new possibilities, challenges 2The quest for an effective HIV vaccine presents new possibilities, challenges 3The quest for an effective HIV vaccine presents new possibilities, challenges 4Decoding protein structures helps illuminate cause of diabetes 2
... walled plates enhance luminescent signals and ... Not treated (or medium binding) polystyrene ... binds biomolecules through passive interactions,• Is ... large molecules, such as antibodies, that ...
... BIP-NC H-IPMIK-OH ... PROTECT FROM LIGHT. HYGROSCOPIC. PACKAGED UNDER INERT ... Bax-Inhibiting Peptide, V5 (Cat. No. 196810) that ... suppress Bax-mediated apoptosis (~200 μM). Purity: ...
...
BD Falcon microtest assay plate. 1536 well 12l, black BD Optilux PS. Polystyrene, nonsterile, no lid (15/sp, 60/ca) Packaging: 15 / pack, 60 / case ...
Biology Products: